A Phase 2 dose ranging trial with ATI-50002 for the topical treatment of patchy alopecia areata.
Phase of Trial: Phase II
Latest Information Update: 08 Aug 2017
At a glance
- Drugs ATI 50002 (Primary)
- Indications Alopecia areata
- Focus Therapeutic Use
- 08 Aug 2017 According to an Aclaris Therapeutics media release, the company has submitted an IND Application to the U.S. FDA. Following FDA clearance of the IND, the company expects to initiate this trial.
- 20 Mar 2017 New trial record
- 15 Mar 2017 According to an Aclaris Therapeutics media release, the company plans to initiate this trial in the second half of 2017.